Paclitaxel in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

Objective. The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. Methods. The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m2 (135 mg/m2 in...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Gynecologic oncology Ročník 83; číslo 2; s. 268 - 270
Hlavní autoři:	Curtin, John P., Blessing, John A., Soper, John T., DeGeest, Koen
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	San Diego, CA Elsevier Inc 01.11.2001 Elsevier
Témata:	Adult Aged Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Carcinosarcoma - drug therapy Drug Administration Schedule Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Infusions, Intravenous Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Paclitaxel - adverse effects Paclitaxel - therapeutic use Tumors Uterine Neoplasms - drug therapy Human Antineoplastic agent Relapse Treatment resistance Treatment efficiency Malignant tumor Female genital diseases Chemotherapy Treatment Uterus Taxane derivatives Paclitaxel Uterine diseases Adult Female Spindle cell carcinoma
ISSN:	0090-8258, 1095-6859
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Objective. The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. Methods. The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m2 (135 mg/m2 in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy. Results. A total of 53 patients were entered into the study between September 1994 and January 1997; 44 patients were evaluable for response. The median age of the patients treated was 65 years (range: 38–79). Twenty-six patients had heterologous mixed mesodermal tumors (MMTs) and 18 patients had homologous tumors. A median of three courses were administered (range: 1–18). Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy. Eight patients (18.2%) had a response to paclitaxel: four patients had a complete response and four had a partial response. Neutropenia was the most common toxic effect. Conclusions. Paclitaxel had moderate activity in patients with carcinosarcoma of the uterus. The GOG is currently studying the combination of paclitaxel and ifosfamide versus ifosfamide alone for patients with advanced or recurrent carcinosarcoma of the uterus.
AbstractList	The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m(2) (135 mg/m(2) in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy. A total of 53 patients were entered into the study between September 1994 and January 1997; 44 patients were evaluable for response. The median age of the patients treated was 65 years (range: 38-79). Twenty-six patients had heterologous mixed mesodermal tumors (MMTs) and 18 patients had homologous tumors. A median of three courses were administered (range: 1-18). Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy. Eight patients (18.2%) had a response to paclitaxel: four patients had a complete response and four had a partial response. Neutropenia was the most common toxic effect. Paclitaxel had moderate activity in patients with carcinosarcoma of the uterus. The GOG is currently studying the combination of paclitaxel and ifosfamide versus ifosfamide alone for patients with advanced or recurrent carcinosarcoma of the uterus. The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments.OBJECTIVEThe goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments.The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m(2) (135 mg/m(2) in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy.METHODSThe Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m(2) (135 mg/m(2) in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy.A total of 53 patients were entered into the study between September 1994 and January 1997; 44 patients were evaluable for response. The median age of the patients treated was 65 years (range: 38-79). Twenty-six patients had heterologous mixed mesodermal tumors (MMTs) and 18 patients had homologous tumors. A median of three courses were administered (range: 1-18). Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy. Eight patients (18.2%) had a response to paclitaxel: four patients had a complete response and four had a partial response. Neutropenia was the most common toxic effect.RESULTSA total of 53 patients were entered into the study between September 1994 and January 1997; 44 patients were evaluable for response. The median age of the patients treated was 65 years (range: 38-79). Twenty-six patients had heterologous mixed mesodermal tumors (MMTs) and 18 patients had homologous tumors. A median of three courses were administered (range: 1-18). Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy. Eight patients (18.2%) had a response to paclitaxel: four patients had a complete response and four had a partial response. Neutropenia was the most common toxic effect.Paclitaxel had moderate activity in patients with carcinosarcoma of the uterus. The GOG is currently studying the combination of paclitaxel and ifosfamide versus ifosfamide alone for patients with advanced or recurrent carcinosarcoma of the uterus.CONCLUSIONSPaclitaxel had moderate activity in patients with carcinosarcoma of the uterus. The GOG is currently studying the combination of paclitaxel and ifosfamide versus ifosfamide alone for patients with advanced or recurrent carcinosarcoma of the uterus. Objective. The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. Methods. The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m2 (135 mg/m2 in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy. Results. A total of 53 patients were entered into the study between September 1994 and January 1997; 44 patients were evaluable for response. The median age of the patients treated was 65 years (range: 38–79). Twenty-six patients had heterologous mixed mesodermal tumors (MMTs) and 18 patients had homologous tumors. A median of three courses were administered (range: 1–18). Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy. Eight patients (18.2%) had a response to paclitaxel: four patients had a complete response and four had a partial response. Neutropenia was the most common toxic effect. Conclusions. Paclitaxel had moderate activity in patients with carcinosarcoma of the uterus. The GOG is currently studying the combination of paclitaxel and ifosfamide versus ifosfamide alone for patients with advanced or recurrent carcinosarcoma of the uterus.
Author	DeGeest, Koen Soper, John T. Blessing, John A. Curtin, John P.
Author_xml	– sequence: 1 givenname: John P. surname: Curtin fullname: Curtin, John P. organization: Department of Obstetrics and Gynecology, Cornell University Medical Center, Memorial Sloan–Kettering Cancer Center, New York, New York, 10021 – sequence: 2 givenname: John A. surname: Blessing fullname: Blessing, John A. organization: Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, New York, 14263 – sequence: 3 givenname: John T. surname: Soper fullname: Soper, John T. organization: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, 27710 – sequence: 4 givenname: Koen surname: DeGeest fullname: DeGeest, Koen organization: Department of Obstetrics and Gynecology, Rush Medical College, Chicago, Illinois, 60612
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14158589$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11606082$$D View this record in MEDLINE/PubMed
BookMark	eNp9kUFv1DAQRi1URLeFK0fkC9yy2E7ieLlVK1gqVSoS7dlyJpNiSOzFdiry73HYLUiVymks673RzHxn5MR5h4S85mzNGZPv72bn14Ixvpails_IirNNXUhVb07IirENK5So1Sk5i_E7Y6xkXLwgp5xLJpkSK6K_GBhsMr9woNbR9A3pTUCTRnSJ-p5uTQDrfMzFj2b5WZDbhGGKH-gF3c0OwQ_-zgK9dn9eM90FP-3p1zR180vyvDdDxFfHek5uP3282X4urq53l9uLqwIqXqeibbumqlXDQSohAJu-4h1va-hLhrJWG141ZWeUAGFa3tdtrwC6Fpmo2g2asjwn7w5998H_nDAmPdoIOAzGoZ-iboTgTCqZwTdHcGpH7PQ-2NGEWT-cJANvj4CJYIY-GAc2_uPyvCoPlLnqwEHwMQbsNeQ7JutdCsYOmjO9JKSXhPSSkF4Sytr6kfa381OCOgiYz3dvMegIFh1gZwNC0p23T6vykZqzdjZv9QPn_4m_ATZTuMc
CODEN	GYNOA3
CitedBy_id	crossref_primary_10_1111_j_1525_1438_2006_00560_x crossref_primary_10_1016_j_ygyno_2012_05_024 crossref_primary_10_1016_j_ygyno_2004_05_048 crossref_primary_10_1016_j_ygyno_2011_10_008 crossref_primary_10_1038_bjc_2011_316 crossref_primary_10_2217_cns_2017_0015 crossref_primary_10_1016_j_gynor_2012_12_010 crossref_primary_10_1007_s10269_006_0545_5 crossref_primary_10_1016_j_ygyno_2005_05_015 crossref_primary_10_1111_j_1525_1438_2006_00532_x crossref_primary_10_1016_j_ygyno_2005_01_041 crossref_primary_10_1111_j_1743_7563_2011_01513_x crossref_primary_10_1007_s13193_022_01563_1 crossref_primary_10_1016_j_critrevonc_2007_06_011 crossref_primary_10_1016_j_critrevonc_2014_10_013 crossref_primary_10_1016_j_bpobgyn_2011_06_003 crossref_primary_10_3816_COC_2010_n_011 crossref_primary_10_1016_j_ygyno_2015_03_041 crossref_primary_10_1016_j_ygyno_2007_08_084 crossref_primary_10_1016_j_lungcan_2007_05_022 crossref_primary_10_1111_j_1525_1438_2006_00536_x crossref_primary_10_3802_jgo_2025_36_e64 crossref_primary_10_1016_j_ygyno_2010_03_024 crossref_primary_10_1016_j_ygyno_2014_02_036 crossref_primary_10_1200_JCO_2009_26_8326 crossref_primary_10_1016_j_ygyno_2012_07_095 crossref_primary_10_1007_s13577_016_0154_6 crossref_primary_10_1097_IGC_0000000000000215 crossref_primary_10_1136_ijgc_00009577_200603000_00062 crossref_primary_10_1093_annonc_mds359 crossref_primary_10_1007_s00259_007_0533_z crossref_primary_10_3892_ol_2012_1094 crossref_primary_10_1016_S0959_8049_02_00114_4 crossref_primary_10_1097_PAS_0b013e3181161ba3 crossref_primary_10_1586_era_12_158 crossref_primary_10_3109_01443615_2010_549971 crossref_primary_10_1200_JCO_2007_10_8431 crossref_primary_10_1007_s11864_015_0370_4 crossref_primary_10_1111_IGC_0b013e3181a8ef22 crossref_primary_10_1111_j_1743_7563_2006_00037_x crossref_primary_10_1586_14737140_8_2_219 crossref_primary_10_1007_s10147_013_0658_y crossref_primary_10_1007_s13577_025_01225_8 crossref_primary_10_1097_MD_0000000000003246 crossref_primary_10_1007_s00404_012_2466_4 crossref_primary_10_2174_1381612826666200917145551 crossref_primary_10_1136_ijgc_00009577_200605000_00063 crossref_primary_10_1136_ijgc_00009577_200605000_00062 crossref_primary_10_1016_j_ygyno_2020_10_043 crossref_primary_10_1016_j_ygyno_2016_10_026 crossref_primary_10_1136_ijgc_2022_004073 crossref_primary_10_2217_17455057_1_3_375 crossref_primary_10_1016_j_ygyno_2004_07_041 crossref_primary_10_1200_JCO_2006_06_4907 crossref_primary_10_1016_j_clon_2008_04_002 crossref_primary_10_1016_j_ygyno_2004_12_006 crossref_primary_10_1016_j_humpath_2007_01_012 crossref_primary_10_1016_j_ygyno_2008_05_017 crossref_primary_10_1016_j_ygyno_2013_05_015
Cites_doi	10.1016/0360-3016(86)90011-8 10.1002/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E 10.1016/0002-9378(89)90507-3 10.1006/gyno.1996.0103 10.1006/gyno.2000.6001 10.1006/gyno.1994.1081 10.1200/JCO.1994.12.12.2654
ContentType	Journal Article
Copyright	2001 Academic Press 2002 INIST-CNRS Copyright 2001 Academic Press.
Copyright_xml	– notice: 2001 Academic Press – notice: 2002 INIST-CNRS – notice: Copyright 2001 Academic Press.
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1006/gyno.2001.6256
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1095-6859
EndPage	270
ExternalDocumentID	11606082 14158589 10_1006_gyno_2001_6256 S0090825801962560
Genre	Multicenter Study Clinical Trial, Phase II Research Support, U.S. Gov't, P.H.S Clinical Trial Journal Article
GrantInformation_xml	– fundername: NCI NIH HHS grantid: CA 27469 – fundername: NCI NIH HHS grantid: CA 37517
GroupedDBID	--- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- ~HD AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW LCYCR RIG 9DU AAYXX CITATION AGCQF AGRNS IQODW CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c415t-bbd745871c6822ce7f41d1b5cf30e65891473da82c2ab1f5bf8ccdbe024b9ea33
ISICitedReferencesCount	78
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000172049600014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0090-8258
IngestDate	Thu Oct 02 06:47:44 EDT 2025 Wed Feb 19 01:27:56 EST 2025 Mon Jul 21 09:11:03 EDT 2025 Sat Nov 29 05:52:21 EST 2025 Tue Nov 18 21:25:11 EST 2025 Fri Feb 23 02:31:03 EST 2024 Tue Oct 14 19:30:22 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	Human Antineoplastic agent Relapse Treatment resistance Treatment efficiency Malignant tumor Female genital diseases Chemotherapy Treatment Uterus Taxane derivatives Paclitaxel Uterine diseases Adult Female Spindle cell carcinoma
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright 2001 Academic Press.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c415t-bbd745871c6822ce7f41d1b5cf30e65891473da82c2ab1f5bf8ccdbe024b9ea33
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
PMID	11606082
PQID	72210686
PQPubID	23479
PageCount	3
ParticipantIDs	proquest_miscellaneous_72210686 pubmed_primary_11606082 pascalfrancis_primary_14158589 crossref_citationtrail_10_1006_gyno_2001_6256 crossref_primary_10_1006_gyno_2001_6256 elsevier_sciencedirect_doi_10_1006_gyno_2001_6256 elsevier_clinicalkey_doi_10_1006_gyno_2001_6256
PublicationCentury	2000
PublicationDate	2001-11-01
PublicationDateYYYYMMDD	2001-11-01
PublicationDate_xml	– month: 11 year: 2001 text: 2001-11-01 day: 01
PublicationDecade	2000
PublicationPlace	San Diego, CA
PublicationPlace_xml	– name: San Diego, CA – name: United States
PublicationTitle	Gynecologic oncology
PublicationTitleAlternate	Gynecol Oncol
PublicationYear	2001
Publisher	Elsevier Inc Elsevier
Publisher_xml	– name: Elsevier Inc – name: Elsevier
References	Rowinsky (RF12) 1997; 11 Currie, Blessing, McGehee, Soper, Berman (RF9) 1996; 61 Eisenhauer, ten Bokkel Huinink, Swenerton, Gianni, Myles, van der Burg, Kerr, Vermorken, Suer, Colombo (RF11) 1994; 12 Major, Blessing, Silverberg, Morrow, Creasman, Currie, Yordan, Brady (RF1) 1993; 71 Thigpen, Blessing, Orr, DiSaia (RF4) 1986; 70 Slayton, Blessing, DiSaia, Christopherson (RF7) 1987; 71 Sutton, Brunetto, Kilgore, Soper, McGehee, Olt, Lentz, Sorosky, Hsiu (RF10) 2000; 79 Asbury (RF8) 1996; 19 Hornback, Omura, Major (RF2) 1986; 12 Sutton, Blessing, Rosenshein, Photopulos, DiSaia (RF5) 1989; 161 Sutton, Blessing, Homesley, Malfetano (RF6) 1994; 53 Omura, Major, Blessing, Sedlacek, Thigpen, Creasman, Zaino (RF3) 1983; 52 Asbury (10.1006/gyno.2001.6256_RF8) 1996; 19 Thigpen (10.1006/gyno.2001.6256_RF4) 1986; 70 Currie (10.1006/gyno.2001.6256_RF9) 1996; 61 Sutton (10.1006/gyno.2001.6256_RF6) 1994; 53 Sutton (10.1006/gyno.2001.6256_RF5) 1989; 161 Slayton (10.1006/gyno.2001.6256_RF7) 1987; 71 Hornback (10.1006/gyno.2001.6256_RF2) 1986; 12 Eisenhauer (10.1006/gyno.2001.6256_RF11) 1994; 12 Omura (10.1006/gyno.2001.6256_RF3) 1983; 52 Rowinsky (10.1006/gyno.2001.6256_RF12) 1997; 11 Major (10.1006/gyno.2001.6256_RF1) 1993; 71 Sutton (10.1006/gyno.2001.6256_RF10) 2000; 79
References_xml	– volume: 11 start-page: 7 year: 1997 end-page: 19 ident: RF12 article-title: The taxanes dosing and scheduling consideration [review] publication-title: Oncology (Huntingt) – volume: 79 start-page: 147 year: 2000 end-page: 153 ident: RF10 article-title: A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group (GOG) study publication-title: Gynecol Oncol – volume: 71 start-page: 661 year: 1987 end-page: 662 ident: RF7 article-title: Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus publication-title: Cancer Treat Rep – volume: 52 start-page: 626 year: 1983 end-page: 632 ident: RF3 article-title: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas publication-title: Cancer – volume: 53 start-page: 24 year: 1994 end-page: 26 ident: RF6 article-title: A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study publication-title: Gynecol Oncol – volume: 19 start-page: 400 year: 1996 end-page: 402 ident: RF8 article-title: Blessing JA publication-title: Moore D. A phase II trail of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: a Gynecologic Oncology Group study. Am J Clin Oncol – volume: 12 start-page: 2121 year: 1986 end-page: 2130 ident: RF2 article-title: Observations on the use of adjuvant radiation therapy in the treatment of stage I and II uterine sarcoma by the Gynecologic Oncology Group publication-title: Int J Radiat Oncol Biol Phys – volume: 61 start-page: 94 year: 1996 end-page: 96 ident: RF9 article-title: Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study publication-title: Gynecol Oncol – volume: 161 start-page: 309 year: 1989 end-page: 312 ident: RF5 article-title: Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study) publication-title: Am J Obstet Gynecol – volume: 71 start-page: 1702 year: 1993 end-page: 1709 ident: RF1 article-title: Prognostic factors in early-stage uterine sarcoma publication-title: a Gynecologic Oncology Group study. Cancer – volume: 70 start-page: 271 year: 1986 end-page: 274 ident: RF4 article-title: Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study publication-title: Cancer Treat Rep – volume: 12 start-page: 2654 year: 1994 end-page: 2666 ident: RF11 article-title: European–Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion publication-title: J Clin Oncol – volume: 12 start-page: 2121 year: 1986 ident: 10.1006/gyno.2001.6256_RF2 article-title: Observations on the use of adjuvant radiation therapy in the treatment of stage I and II uterine sarcoma by the Gynecologic Oncology Group publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(86)90011-8 – volume: 70 start-page: 271 year: 1986 ident: 10.1006/gyno.2001.6256_RF4 article-title: Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study publication-title: Cancer Treat Rep – volume: 11 start-page: 7 year: 1997 ident: 10.1006/gyno.2001.6256_RF12 article-title: The taxanes dosing and scheduling consideration [review] publication-title: Oncology (Huntingt) – volume: 52 start-page: 626 year: 1983 ident: 10.1006/gyno.2001.6256_RF3 article-title: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas publication-title: Cancer doi: 10.1002/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E – volume: 161 start-page: 309 year: 1989 ident: 10.1006/gyno.2001.6256_RF5 article-title: Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study) publication-title: Am J Obstet Gynecol doi: 10.1016/0002-9378(89)90507-3 – volume: 61 start-page: 94 year: 1996 ident: 10.1006/gyno.2001.6256_RF9 article-title: Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study publication-title: Gynecol Oncol doi: 10.1006/gyno.1996.0103 – volume: 79 start-page: 147 year: 2000 ident: 10.1006/gyno.2001.6256_RF10 article-title: A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group (GOG) study publication-title: Gynecol Oncol doi: 10.1006/gyno.2000.6001 – volume: 71 start-page: 1702 year: 1993 ident: 10.1006/gyno.2001.6256_RF1 article-title: Prognostic factors in early-stage uterine sarcoma publication-title: a Gynecologic Oncology Group study. Cancer – volume: 53 start-page: 24 year: 1994 ident: 10.1006/gyno.2001.6256_RF6 article-title: A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study publication-title: Gynecol Oncol doi: 10.1006/gyno.1994.1081 – volume: 71 start-page: 661 year: 1987 ident: 10.1006/gyno.2001.6256_RF7 article-title: Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus publication-title: Cancer Treat Rep – volume: 12 start-page: 2654 year: 1994 ident: 10.1006/gyno.2001.6256_RF11 article-title: European–Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion publication-title: J Clin Oncol doi: 10.1200/JCO.1994.12.12.2654 – volume: 19 start-page: 400 year: 1996 ident: 10.1006/gyno.2001.6256_RF8 article-title: Blessing JA publication-title: Moore D. A phase II trail of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: a Gynecologic Oncology Group study. Am J Clin Oncol
SSID	ssj0003012
Score	1.9511342
Snippet	Objective. The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who... The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have...
SourceID	proquest pubmed pascalfrancis crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	268
SubjectTerms	Adult Aged Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Carcinosarcoma - drug therapy Drug Administration Schedule Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Infusions, Intravenous Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Paclitaxel - adverse effects Paclitaxel - therapeutic use Tumors Uterine Neoplasms - drug therapy
Title	Paclitaxel in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0090825801962560 https://dx.doi.org/10.1006/gyno.2001.6256 https://www.ncbi.nlm.nih.gov/pubmed/11606082 https://www.proquest.com/docview/72210686
Volume	83
WOSCitedRecordID	wos000172049600014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1095-6859 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003012 issn: 0090-8258 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zi9swEBbZbCmFUnpveqR6KPRhcTbyIct9C-12e24DyULejC3LJZCVQ5ws2d_SP9uRdSRpSWkLfXGCIjlC83lmJM98g9DLhLEEDIfwwjLoeyGLhJfAxtkjhCalD4NI0fDMfo7Pz9lkkgxbre82F-ZqFkvJ1utk_l9FDW0gbJU6-xfidjeFBvgOQocriB2ufyT4YcYV8fZazGwM49gFkzfJWAs-lVUNH9VlZkMELmB5V7VOUz-7loJrnXj8VXJN0qQPrUaOjNb4s9t9K9PXvdZYWYaCJjxn2HNb_5mKvd2EAh8P3E-jaq4x1LSPXftbcSaETk_5VJnsNXtWQUzSnjtAs0k0OzGe4OWpbHbN4N4TWg-D5-dRZsjCjaLWFW8MIP1trUvZlgH3dSWSX2wD6BeQ3bdr2eR8kh7s_H4i4W7M-kjNR01HMQcph_AAHfpxlLA2Ohx8OJ18dIYedKMmozfzt5ygfXqy-y_7fJ7b86yGJ7HUJVT273EaX2d8F90xmxQ80OC6h1pC3kc3v5gwjAco3WAMTyUGAGGHMVyVeBdjqkV10Rh7jQd4CzXYIgw3CMMNwh6ii3en4zfvPVOpw-PgAC69PC_iMIK9N6fgcHIRlyEpSB5xUACCqsKVYRwUGfO5n-WkjPKScV7kAhzEPBFZEDxCbVlJcYRwIGJRBpEQGeuHeZjkquRCXtJEUFAcrOwgz65lyg2NvaqmMks1ATdN1dqr6qokVWvfQa9c_7kmcNnb88SKJrVpyWBIU8DP3hHEjTAOq3ZEfzumuyP1zaRgJRksVQe9sDBIQdWr93eZFNWqTmPfJyqjq4Mea3RsxhLapwDaJ_8woafo1uZRfYbay8VKPEc3-NVyWi-66CCesK5B_g_5KNeV
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Paclitaxel+in+the+Treatment+of+Carcinosarcoma+of+the+Uterus%3A+A+Gynecologic+Oncology+Group+Study&rft.jtitle=Gynecologic+oncology&rft.au=Curtin%2C+John+P.&rft.au=Blessing%2C+John+A.&rft.au=Soper%2C+John+T.&rft.au=DeGeest%2C+Koen&rft.date=2001-11-01&rft.pub=Elsevier+Inc&rft.issn=0090-8258&rft.eissn=1095-6859&rft.volume=83&rft.issue=2&rft.spage=268&rft.epage=270&rft_id=info:doi/10.1006%2Fgyno.2001.6256&rft.externalDocID=S0090825801962560
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon